[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-neoplasms":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,79,108,142,162,194,235,267,292],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":4,"leadSponsor":42,"locationsCount":45},"100060545","genetic-analysis-of-birt-hogg-dube-syndrome-and-characterization-of-predisposition-to-kidney-cancer-100060545",false,"NCT00033137","Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer","Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts","* INCLUSION CRITERIA:\n\nIndividuals that meet one or more of the following criteria:\n\n-Suspected or known to have phenotype or genotype suggestive of Birt-Hogg-Dube (BHD), such as:\n\n--Individuals with at least one histologically confirmed fibrofolliculomas;\n\nor\n\n--Individuals with clinical evidence of multiple skin papules (without fibrofolliculoma biopsy confirmation) and a personal or family history of spontaneous pneumothorax\u002For kidney cancer;\n\nor\n\n--Individuals with spontaneous pneumothorax and skin papules or kidney cancer and a positive family history of spontaneous pneumothorax, skin papules or kidney cancer;\n\nor\n\n--Individuals with a known germline FLCN gene mutation\n\nOR\n\n-Renal tumor histology consistent with BHD, including, but not limited to those suggestive of chromophobe, hybrid oncocytic neoplasm or oncocytoma.\n\nOR\n\n* Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of BHD.\n\n  -Participants must be \\>= 2 years of age.\n* For children less than 18 years of age, parental permission or legal guardian consent will be obtained.\n\nEXCLUSION CRITERIA:\n\nNone.",true,"ALL","2 Years",{"count":20,"type":21},950,"ESTIMATED","OBSERVATIONAL","This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps-benign tumors involving hair follicles-on the head and neck. People with BHD are at increased risk of developing kidney cancer. Scientists have identified the chromosome (strand of genetic material in the cell nucleus) that contains the BHD gene and the region of the gene on the chromosome. This study will try to learn more about:\n\n* The characteristics and type of kidney tumors associated with BHD\n* The risk of kidney cancer in people with BHD\n* Whether more than one gene causes BHD\n* The genetic mutations (changes) responsible for BHD\n\nIndividuals with known or suspected Birt Hogg-Dube syndrome, and their family members, may be eligible for this study. Candidates will be screened with a family history and review of medical records, including pathology reports for tumors, and films of computed tomography (CT) and magnetic resonance imaging (MRI) scans.\n\nParticipants may undergo various tests and procedures, including the following:\n\n* Physical examination\n* Review of personal and family history with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor\n* Chest and other x-rays\n* Ultrasound (imaging study using sound waves)\n* MRI (imaging study using radiowaves and a magnetic field)\n* CT scans of the chest and abdomen (imaging studies using radiation)\n* Blood tests for blood chemistries and genetic testing\n* Skin evaluation, including a skin biopsy (surgical removal of a small skin tissue sample for microscopic evaluation)\n* Cheek swab or mouthwash to collect cells for genetic analysis\n* Lung function studies\n* Medical photography of skin lesions\n\nThese tests will be done on an outpatient basis in either one day or over 3 to 4 days. When the studies are complete, participants will receive counseling about the findings and recommendations. Individuals with kidney lesions may be asked to return periodically, such as every 3 to 36 months, based on their individual condition, to document the rate of progression of the lesions.",[25,26,27,28],"Kidney Neoplasms","Kidney Cancer","Pneumothorax","FLCN Protein, Human",[27,30,31,32,33,34],"Kidney","Fibrofolliculoma","BHD","Neoplasms","Natural History","RECRUITING","2026-06-16",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":39},"2002-05-13",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100610248","phase-2-translation-of-acoustic-angiography-contrast-enhanced-super-resolution-cesr-imaging-100610248","NCT07225114","Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging","Academic-Industrial Partnership for Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Patient had a diagnostic ultrasound study performed at University of North Carolina\n* Scheduled for a biopsy\n* Lesion visualized on ultrasound\n* Able to provide informed consent\n* Negative urine pregnancy test in women of child-bearing potential\n\nExclusion Criteria:\n\n* Institutionalized subject (prisoner or nursing home patient)\n* Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD)\n* Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®)\n* Active cardiac disease including any of the following\n* Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association)\n* Unstable angina.\n* Severe arrhythmia (i.e., ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes).\n* Myocardial infarction within 14 days prior to the date of proposed Definity® administration.\n* Pulmonary hypertension\n* Cardiac shunts","18 Years",{"count":55,"type":21},40,"INTERVENTIONAL",[58],"PHASE2","This is a 4-arm, single-center study involving 40 participants. Ten healthy volunteers will be enrolled for system imaging optimization, and thirty (30) patients with previously identified lesions in the breast, liver, or kidney-based on prior ultrasound or cross-sectional imaging-will be imaged. Recruitment will be conducted such that ten patients are included from each anatomic region.\n\nThe fourth arm will consist of 10 healthy volunteers who will be imaged to allow optimization of imaging parameters. Optimization is is required again due to the use of a different ultrasound system employing a new imaging technique. Parameters such as frame rate, power, depth of imaging, and linear translation rate will be adjusted during this process.\n\nThe primary objectives of the study are to assess the sensitivity and specificity of Contrast Enhanced Super-Resolution (CESR) imaging in evaluating known lesions in the breast, liver, and kidney. These results will be compared with pathological findings. The secondary objectives are to compare the sensitivity and specificity of CESR imaging with those of traditional B-mode ultrasound in differentiating malignant from benign lesions in these same organs.",[61,25,62],"Breast Cancer","Liver Neoplasms",[64,65,66,67,68],"Definity®","perflutren lipid","healthy volunteers","ultrasound","cross-sectional imaging","2026-06-04",{"date":71,"type":39},"2026-06-08",{"date":73,"type":39},"2025-11-04",{"date":75,"type":21},"2028-12",{"name":77,"class":78},"UNC Lineberger Comprehensive Cancer Center","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100568351","phase-2-cd70-targeted-immunopet-imaging-of-kidney-cancer-100568351","NCT06680089","CD70-targeted immunoPET Imaging of Kidney Cancer","A Study of the Clinical Application of [18F]RCCB6 PET\u002F CT Imaging in the Diagnosis of Kidney Cancer","Inclusion Criteria:\n\n1. Aged 18-80 year-old and of either sex；\n2. Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","80 Years",{"count":88,"type":21},300,[58],"The aim of this study is to establish and optimize the \\[18F\\]RCCB6 PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.",[92,93,25,33],"Urologic Neoplasms","Urogenital Neoplasms",[95,96,97,98],"The cluster of differentiation (CD70)","Kidney tumor","Clear cell renal cell carcinoma","ImmunoPET","2025-12-25",{"date":101,"type":39},"2025-12-31",{"date":103,"type":39},"2024-11-27",{"date":105,"type":21},"2027-11",{"name":107,"class":78},"RenJi Hospital",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":86,"enrollmentInfo":115,"targetDuration":117,"studyType":22,"phases":4,"briefSummary":118,"conditions":119,"keywords":129,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.",{"count":116,"type":21},39,"12 Weeks","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[33,25,92,93,120,121,122,123,124,125,126,127,128],"Female Urogenital Diseases","Male Urogenital Diseases","Urogenital Diseases","Kidney Diseases","Urologic Diseases","Carcinoma","Renal Cell Cancer","Carcinoma, Renal Cell","Antineoplastic Agents",[130,131,132],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":135,"type":39},"2025-12-05",{"date":137,"type":39},"2024-09-01",{"date":139,"type":21},"2026-09-01",{"name":141,"class":78},"Jinling Hospital, China",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":22,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100509720","renal-cancer-monitoring-based-on-ctdna-methylomics-a-prospective-cohort-study-memory-study-100509720","NCT05917106","Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)","Inclusion Criteria:\n\n* Newly diagnosed renal cell carcinoma\n* Without any treatment\n* Agree and accept radical surgical treatment\n* Signed written informed consent\n* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1\n* Follow up protocol and related procedures\n\nExclusion Criteria:\n\n* Had other cancers\n* Had received any antitumor therapy before\n* Known or suspected active autoimmune disease\n* Informed consent is not possible due to medical or psychiatric problems\n* Have clinical symptoms or diseases of the heart that are not well controlled\n* Patients judged by the investigators to be unsuitable for inclusion in this study",{"count":149,"type":21},450,"5 Years","To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.",[125,153,154,25,26],"Renal Cell Carcinoma","RCC",{"date":156,"type":39},"2025-12-11",{"date":158,"type":39},"2022-12-26",{"date":160,"type":21},"2030-06",{"name":141,"class":78},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100298073","genetic-analysis-of-pheochromocytomas-paragangliomas-and-associated-conditions-100298073","NCT03160274","Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","Inclusion Criteria:\n\n* diagnosis of pheochromocytoma and or paraganglioma\n* family member with diagnosis of pheochromocytoma and or paraganglioma\n* diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n* family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition\n\nExclusion Criteria:\n\n* unconfirmed diagnosis of pheochromocytoma and\u002For paraganglioma or associated condition",{"count":169,"type":21},2000,"30 Years","Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma\u002Fparaganglioma of various genetic origins.",[173,174,175,176,25,177,178,179],"Pheochromocytoma","Paraganglioma","Inherited Cancer Syndrome","Associated Conditions","Bone Cancer","Thyroid Neoplasms","Other Cancer",[181,182,183,184],"tumor suppressor gene","oncogene","mutation","susceptibility gene","2025-10-13",{"date":187,"type":39},"2025-10-15",{"date":189,"type":39},"2005-10-19",{"date":191,"type":21},"2030-12-31",{"name":193,"class":78},"The University of Texas Health Science Center at San Antonio",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":56,"phases":203,"briefSummary":205,"conditions":206,"keywords":219,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100511807","phase-1-htl0039732-in-participants-with-advanced-solid-tumours-100511807","NCT05944237","HTL0039732 in Participants With Advanced Solid Tumours","A Cancer Research UK Phase I\u002FIIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours","Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product administration and follow-up.\n2. Phase 1, dose escalation phase\n\n   Part A (HTL0039732 monotherapy):\n   * Histologically or cytologically proven advanced solid tumour, refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the potential participant.\n   * At least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy, or at least one assessable lesion e.g. pleural or peritoneal thickening that does not fulfil RECIST v1.1 criteria for measurable disease.\n\n     a. Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n   * Consent to access and analysis of any available archival tissue or a fresh tumour sample at baseline, if archival tissue is unavailable.\n   * Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n\n   Phase 1 Part B:\n\n   \\- Histologically proven advanced solid tumour where PGE2\u002FEP4 signalling is believed to be more prevalent or significant (such as microsatellite stable colorectal cancer (MSS CRC), gastro-esophageal cancer, head and neck squamous cell carcinoma (HNSCC), mCRPC, pancreatic cancer, lung cancer, bladder cancer, mesothelioma, cervical cancer, renal cancer, sarcoma, pheochromocytoma and cancers with PI3K\u002FAKT\u002FmTOR pathway activating mutations using a clinically-validated assay).\n\n   Phase 2a:\n\n   \\- Histologically proven advanced solid tumour, in line with indications listed below, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the potential participant:\n   1. MSS CRC with PIK3CA or HER2 mutation, and\u002For other driver mutation as agreed with the Sponsor (genomic alteration to have been previously identified using a validated next-generation sequencing method performed on either tumour tissue or circulating tumour DNA \\[ctDNA\\]);\n   2. Gastric or gastroesophageal junction (GOJ) adenocarcinoma;\n   3. Clear cell renal cell carcinoma;\n   4. mCRPC\n\n   Phase 1 Part B and Phase 2a:\n   * Consent to access and analysis of any available archival tissue.\n   * Consent for fresh tumour biopsy samples at baseline and on treatment. However, the following exceptions will be permitted if archival tissue is available at the recruiting site:\n\n     1. Patients with mCRPC: biopsies are not required for those whose only safely accessible lesions are bone metastases that lack an accessible soft tissue component.\n     2. For the first 12 participants in each indication: the on-trial biopsy is optional; and the baseline biopsy is mandatory if there is a safely accessible lesion but may be omitted for patients who have no safely accessible lesion, to permit their inclusion in the study. This will continually be assessed through the study.\n   * Disease refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the participant.\n   * Except for mCRPC, at least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy. Potential participants with mCRPC may instead have had PD according to PCWG3 criteria.\n\n     1. Previously irradiated lesions cannot be counted as target lesions unless clearly progressed after the radiotherapy.\n     2. Lesions that are intended to be biopsied should not be counted as target lesions (those undergoing biopsy must have at least one target lesion that is not intended to be biopsied).\n   * For indications where anti-PD-1\u002FPD-L1 therapy is standard of care (such as clear cell renal cell carcinoma, or gastric or GOJ adenocarcinoma with elevated PD-L1 expression), patients must have received that therapy and must be considered to have had progressive disease by the Investigator either on, or within 6 months after, that treatment.\n3. Life expectancy of at least 12 weeks.\n4. Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Haematological and biochemical indices within the protocol specified ranges.\n6. Stable thyroid function tests. Stable doses of thyroxine replacement are permitted.\n7. Aged 18 years or over at the time consent is given.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative reasons), chemotherapy, non chemotherapy systemic anti-cancer therapy (apart from life-long hormone suppression such as luteinising hormone-releasing agents in participants with mCRPC) or investigational medicinal products during the 4 weeks prior to enrolment; or first dose of an immunotherapy during the previous 12 weeks before first dose of HTL0039732.\n2. Ongoing toxic manifestations of previous treatments that are Grade \\>1 per CTCAE v5.0.\n3. Any central nervous system metastases (unless potential participants have had local therapy and are asymptomatic, radiologically stable and have been off steroids for ≥4 weeks prior to enrolment).\n4. Women of child-bearing potential (or who are already pregnant or lactating). Exceptions apply.\n5. Men with partners of childbearing potential. Exceptions apply.\n6. Major thoracic or abdominal surgery from which the potential participant has not yet recovered.\n7. At high medical risk because of non-malignant systemic disease, including active uncontrolled infection.\n8. Known history of current or latent tuberculosis, HIV or Hepatitis B or C infection.\n9. Prior treatment with EP4 inhibitor.\n10. Treatment with selective cyclooxygenase-2 inhibitor in the 8 weeks prior to enrolment.\n11. Known hypersensitivity or intolerance to hydroxypropyl methylcellulose.\n12. Use of systemic immunosuppressive agent in the 2 weeks prior to enrolment. Exceptions apply.\n13. Significant cardiovascular disease.\n14. Known active peptic ulcer disease, or symptoms of gastritis, dyspepsia or gastro-esophageal reflux disease (one or more episodes per week).\n15. Current or planned participation in another interventional clinical trial, whilst taking part in this trial of HTL0039732.\n16. Limited ability to swallow or absorb oral medications.\n17. Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the potential participant.\n\n    Phase 1 Part B and Phase 2a:\n18. Any live vaccines in the 4 weeks prior to enrolment.\n19. Diagnosis of immunodeficiency.\n20. Active autoimmune disease requiring systemic treatment in the 2 years prior to enrolment.\n21. History or clinical suspicion of interstitial lung disease, history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.\n22. Hypersensitivity to atezolizumab or any of its excipients.\n23. Prior adverse reaction to cancer immunotherapy that required steroid or other immunosuppressive treatment or led to discontinuation of that treatment.",{"count":202,"type":21},150,[204,58],"PHASE1","The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.",[33,207,208,209,210,211,212,213,214,215,216,25,217,218],"Prostatic Neoplasms, Castration-Resistant","Stomach Neoplasms","Esophageal Neoplasms","Head and Neck Neoplasms","Colorectal Neoplasms","Pancreatic Neoplasms","Lung Neoplasms","Urinary Bladder Neoplasms","Mesothelioma, Malignant","Uterine Cervical Neoplasms","Sarcoma","Pheochromocytomas",[220,221,222,223,224],"EP4 antagonist","Anti-PD-1\u002FPD-L1 agents","PGE2","EP4","COX inhibitor","2025-06-05",{"date":227,"type":39},"2025-06-08",{"date":229,"type":39},"2023-07-13",{"date":231,"type":21},"2027-06",{"name":233,"class":78},"Cancer Research UK",5,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":56,"phases":245,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":234},"100557309","planning-operative-strategy-using-a-digital-renal-artery-clamping-tool-100557309","NCT06536439","Planning Operative Strategy Using a Digital Renal Artery Clamping Tool","Planning Operative Strategy Using a Digital Renal Artery Clamping Tool: a Randomized Controlled Trial Evaluating the DIPLANN 3D Model for Selective Arterial Clamping During Robot-Assisted Partial Nephrectomy","PODRACING","Inclusion Criteria:\n\n* aged 18 years or above\n* cT1-2 N0 M0 renal mass\n* planned to undergo RAPN\n* multiphase CT scan with arterial phase available\n* voluntary given and written informed consent\n* sufficient in at least one of the study languages: Dutch, English, French\n\nFor the primary objective, SC needs to be deemed possible either according to the DIPLANN-tool in combination with conventional CT imaging or according to conventional CT imaging only, as assessed by an independent surgeon (between inclusion and randomization) who will not be involved in the RAPN surgical procedure, in order to be included in the analysis set. On the DIPLANN tool, SC is deemed feasible if \\>= 90% tumor ischemia and \\\u003C= 70% renal parenchyma ischemia can be achieved. If these criteria are met, but it is technically or anatomically not feasible according to the independent surgeon to perform SC, he can deviate from these criteria and thus claim SC is not deemed possible. The results for the total population (patients in which SC is deemed possible AND impossible pre-operatively by an independent surgeon) will also be analyzed as a secondary objective.\n\nExclusion Criteria:\n\n* \\> 3 ipsilateral renal masses\n* women who are pregnant or breastfeeding\n* previous renal surgery that is expected to complicate renal cancer surgery\n* cT ≥ 3\n* planned off-clamp resection\n* cognitive disorder which impedes with completing study questionnaires",{"count":244,"type":21},235,[246],"NA","A proposed new tool ('DIPLANN-tool' - Digital Planning in Nephrectomy) for predicting kidney perfusion zones on a segmented 3D model during robot-assisted partial nephrectomy (RAPN) for localized renal cancer demonstrated high accuracy when planning selective clamping (SC) for RAPN. However, the tool's clinical added value still needs to be confirmed. Therefore, a randomized controlled trial using a study and control group is the preferred study design.\n\nExperimental group: the use of the DIPLANN-tool + conventional computed tomography (CT) imaging for preoperative planning and perioperative guidance during RAPN.\n\nControl group: the use of only conventional CT imaging for preoperative planning and perioperative guidance during RAPN (= current standard of care).\n\nThe primary endpoint is planning and performing as planned a SC strategy. Secondary endpoints include patients' health, patients' insight and surgeons' benefits.",[26,25,123,249,153,250],"Renal Cancer","Renal Disease",[26,153,252,253,254,255,256,257],"Minimally Invasive Surgery","Robot-Assisted Surgery","Robot-Assisted Partial Nephrectomy","RAPN","3D","Perfusion Zone","2025-03-26",{"date":260,"type":39},"2025-04-01",{"date":262,"type":39},"2024-06-27",{"date":264,"type":21},"2027-01-01",{"name":266,"class":78},"University Hospital, Ghent",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":274,"maxAge":86,"enrollmentInfo":275,"targetDuration":4,"studyType":56,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":291,"locationsCount":45},"100571102","zero-ischemia-robot-assisted-mwa-assisted-suture-less-tumor-enucleation-of-rcc-with-t1-stage-100571102","NCT06715878","Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage","Zero Ischemia Robot-Assisted Microwave Ablation Assisted Suture-less Enucleation of Renal Cell Carcinoma With T1 Stage: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma\n2. patients scheduled for robot-assisted laparoscopic nephron sparing surgery\n3. patients with normal contralateral renal function (differential renal function of \\>40% as determined by radionuclide scintigraphy)\n4. patients agreeable to participate in this long-term follow-up study\n\nExclusion Criteria:\n\n1. patients' age \\>80 years\n2. patients with other renal diseases (including kidney stone, glomerular nephritis, etc.)which might affect the renal function of the operative kidney\n3. patients not able to tolerate the robot-assisted laparoscopic procedure\n4. patients with previous renal surgery or history of any inflammatory conditions of the operative kidney\n5. patients with the renal tumor involving urinary collecting system or distance from the tumor edge to the collecting system ≤ 4 mm","15 Years",{"count":276,"type":21},80,[246],"Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for T1a renal cell carcinoma (RCC) in a randomized clinical trial in single center. The investigators want to explore this technique to robotic surgery and add suture-less technique to T1 RCC patients in randomized clinical trial.",[25],[281,282,283,284],"Microwave ablation","Nephronsparing surgery","Zero ischemia","suture less","2024-12-08",{"date":287,"type":39},"2024-12-10",{"date":289,"type":39},"2024-03-01",{"date":101,"type":21},{"name":107,"class":78},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":56,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":45},"100456072","cryaoablation-assisted-partial-nephrectomy-a-non-ischemic-approach-100456072","NCT05218811","Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach","Cryotherapy and Robotic Assisted Non Ischemic Nephron Sparring Surgery","RCAPN","Inclusion Criteria:\n\n* Patients with ages between 45-90-year-old.\n* Renal tumor ≤ 7 cm in the greatest extension, \\>50% exophitic.\n\nExclusion Criteria:\n\n* Prior renal surgery\n* M1 Disease","55 Years","65 Years",{"count":202,"type":21},[246],"Patients with renal masses eligible to partial nephrectomy often require arterial ischemia to control or prevent blood loss during this surgical procedure. This study aims to determine the safety and efficacy of renal cryoablation at the tumor bed, as a substitute measure or technique vs total or selective arterial renal ischemia.",[25],"2023-01-24",{"date":308,"type":39},"2023-01-26",{"date":310,"type":39},"2020-05-15",{"date":312,"type":21},"2041-05-15",{"name":314,"class":78},"Urological Research Network, LLC"]